First data from a new Nestlé Health Science sponsored study (PLATYPUS study), evaluating the safety and benefits of an amino acid-based formula (AAF) supplemented with two Human Milk Oligosaccharides (HMO;2’FL and LNnT) in infants and young children with moderate to severe cow’s milk protein allergy (CMPA), was presented at EAACI 2021.
The data presented showed that the AAF containing this HMO blend is safe, promotes normal growth and is effective for those with moderate to severe CMPA, a particularly vulnerable patient population.
Data already presented from studies in the same clinical trial program (IVORY & CINNAMON )showed that an extensively hydrolysed formula supplemented with the same HMO blend, is safe, hypoallergenic, reduces the frequency of respiratory tract infections, positively shapes the gut microbiome and supports normal growth in the wider population of infants with CMPA.
These studies also corroborate findings from another Nestlé-sponsored clinical trial in healthy infants fed a standard infant formula containing the same HMO blend. A shift was observed in the gut microbiota to be closer to that of healthy breastfed infants, which was linked in the study to fewer lower respiratory tract infections and lower use of antibiotics.